| PLx Pharma is a pharmaceutical company focused on developing its PLxGuard delivery system. Co.'s PLxGuard delivery system works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal tract. Co.'s primary product, VAZALORE 325 mg, is a formulation of aspirin using the PLxGuard delivery system to provide antiplatelet effectiveness for vascular disease prevention and treatment and reduce gastric side effects. Co. is focused on collecting the data, including initiating a bioequivalence study, required for post-approval manufacturing changes for VAZALORE 325 mg and to support approval of low dose VAZALORE 81 mg. We show 22 historical shares outstanding datapoints in our coverage of PLXP's shares outstanding history.|
Understanding the changing numbers of PLXP shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like PLXP versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching PLXP by allowing them to research PLXP shares outstanding history
as well as any other stock in our coverage universe.